Vesilute

Research Overview

Vesilute is a synthetic tripeptide belonging to the Khavinson class of short-chain bioregulatory peptides, composed of the amino acid sequence Lysine-Glutamic Acid-Aspartic Acid (KED). Developed through the research program of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Vesilute represents one of a family of tissue-specific peptide bioregulators designed to study vascular and endothelial biology at the cellular level. Research into this compound centers on its proposed interactions with vascular tissue gene expression and its potential role as a molecular signal in endothelial cell maintenance. As a vascular-targeting bioregulator, Vesilute serves as a valuable research tool for scientists investigating the molecular mechanisms underlying vessel wall homeostasis.

The scientific interest in Vesilute arises from the broader hypothesis that short peptides derived from specific organ tissues may exhibit selective affinity for homologous cell types, modulating gene transcription in a tissue-targeted manner. Laboratory studies investigate how the KED sequence interacts with chromatin structures and transcription factors relevant to vascular biology, including pathways governing endothelial cell proliferation, extracellular matrix production, and vascular tone regulation. Researchers examining vascular aging models frequently include Vesilute in comparative panels alongside other bioregulatory peptides such as Crystagen and Thymogen, enabling cross-tissue analysis of peptide bioregulator activity within in vitro and in vivo preclinical systems.

Preclinical research examining Vesilute has explored its relevance across several vascular biology subfields, including endothelial function research, angiogenic signaling, and arterial wall remodeling. Studies utilizing rodent models of vascular impairment have positioned this tripeptide as a probe for understanding how short peptide signals influence microvascular and macrovascular tissue responses. Its compact molecular architecture — only three amino acids — facilitates cellular uptake studies and makes it a tractable subject for pharmacokinetic modeling in comparison to larger peptide scaffolds. Researchers interested in tissue repair mechanisms also examine Vesilute alongside compounds such as Cortagen and BPC-157 to contextualize tissue-specific bioregulatory effects across organ systems.

Molecular Characteristics

Complete Specifications:

• CAS Number: Not formally assigned (research compound)
• Molecular Weight: ~390 Da
• Molecular Formula: C₁₄H₂₄N₄O₈
• Sequence: Lys-Glu-Asp (KED)
• Peptide Length / Classification: Tripeptide; vascular bioregulator
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in sterile water and aqueous buffers; limited solubility in organic solvents

The molecular architecture of Vesilute is characterized by its three charged amino acid residues, each contributing distinct functional groups that facilitate electrostatic interactions with biological macromolecules. The lysine residue provides a positively charged ε-amino group at physiological pH, while both glutamic acid and aspartic acid contribute negatively charged carboxylate side chains, creating an overall zwitterionic charge distribution within the peptide at neutral pH. This charge configuration is considered central to Vesilute’s proposed capacity to interact with DNA-binding proteins and chromatin-associated regulatory elements in vascular cell nuclei.

The low molecular weight of approximately 390 Da places Vesilute within an optimal size range for passive membrane diffusion studies, distinguishing it from larger peptide bioregulators that require active transport mechanisms for cellular uptake. Researchers designing cellular penetration assays appreciate this property, as it reduces confounding variables related to transporter expression levels across different vascular cell subtypes. The peptide’s relatively simple structure also facilitates solid-phase synthesis at high purity, supporting reproducible research-grade preparations suitable for in vitro mechanistic studies.

Pharmacokinetic Profile in Research Models

Absorption and Distribution

• In vitro membrane permeability assays suggest moderate passive diffusion characteristics consistent with Vesilute’s low molecular weight and amphipathic charge profile
• Radiolabeled tracer studies in rodent models have examined tissue distribution patterns with particular emphasis on accumulation within aortic endothelium and arterial wall tissue
• Plasma protein binding remains an active area of inquiry; preliminary findings suggest low-to-moderate binding affinity that supports free peptide availability in experimental systems
• Blood-brain barrier penetration is considered minimal based on structural analysis, relevant when designing multi-tissue research panels

Bioactivity Dynamics

• Gene expression studies in human umbilical vein endothelial cells (HUVECs) have been used to profile transcriptional responses to Vesilute exposure across a range of laboratory concentrations
• Research timelines in cell culture experiments typically span 24–72 hours to capture early and late transcriptional responses within endothelial populations
• Concentration-response relationships are a primary focus in bioactivity investigations, with researchers characterizing effective concentration ranges for downstream pathway activation
• Pulse-chase experiments have been employed to examine reversibility of observed cellular effects following Vesilute washout in culture systems

Metabolic Considerations

• Tripeptides of this class are generally susceptible to aminopeptidase and dipeptidyl peptidase activity in plasma and tissue homogenates; researchers account for this through stability assays prior to in vivo work
• Mass spectrometry fragmentation patterns of Vesilute metabolites have been characterized to distinguish intact peptide signal from degradation products in biological matrices
• Lyophilization and controlled reconstitution protocols are employed to minimize pre-experimental degradation and ensure reproducibility across research cohorts

Research Applications

Endothelial Function Research

• Investigation of eNOS (endothelial nitric oxide synthase) gene expression modulation in endothelial cell lines following Vesilute exposure
• Assessment of endothelial barrier integrity using transendothelial electrical resistance (TEER) assays in monolayer culture systems
• Examination of intercellular adhesion molecule (ICAM-1, VCAM-1) expression profiles relevant to vascular inflammation models
• Research into endothelial-to-mesenchymal transition (EndMT) markers in models of vascular fibrosis and remodeling

Endothelial dysfunction represents a central pathophysiological axis in a wide range of vascular conditions studied in preclinical research. Vesilute serves as a molecular probe in these investigations, allowing researchers to characterize transcriptional and proteomic changes within endothelial cell populations under conditions designed to mimic vascular stress, oxidative challenge, or inflammatory stimulation. Comparative studies alongside GHK-Cu have been used to profile peptide-specific versus copper-dependent mechanisms of endothelial gene regulation.

Vascular Repair and Angiogenesis Models

• Scratch wound and tube formation assays examining the role of Vesilute in endothelial migration and capillary-like network organization in Matrigel systems
• Vascular endothelial growth factor (VEGF) pathway analysis in Vesilute-exposed endothelial cultures using ELISA and gene expression profiling
• Three-dimensional vascular organoid models investigating spatial aspects of vessel organization in the presence of bioregulatory peptide signals
• Ex vivo aortic ring assays providing a tissue-level model to examine angiogenic sprouting responses to Vesilute in intact vessel preparations

Angiogenesis research encompasses a broad range of preclinical disciplines including wound healing biology, tumor vasculature investigation, and developmental vascular biology. Vesilute’s proposed vascular tissue affinity makes it a relevant research tool in studies designed to map signaling cascades that regulate new vessel formation and endothelial tip-cell versus stalk-cell specification.

Vascular Aging and Senescence Studies

• Replicative senescence assays in primary endothelial cells examining senescence-associated secretory phenotype (SASP) biomarkers following Vesilute treatment in aged cell populations
• Telomere length analysis as a surrogate marker of replicative aging in endothelial cultures maintained with Vesilute versus vehicle control
• Epigenetic clock analysis using DNA methylation arrays to assess aging-associated methylation signatures in Vesilute-exposed vascular tissue samples
• Aged rodent vascular models providing in vivo contexts for examining bioregulatory peptide effects on age-associated vascular gene expression programs

Vascular aging research is a growing field within gerontology and cardiovascular biology. Cardiogen, another Khavinson bioregulatory peptide targeting cardiac tissue, is frequently used in parallel with Vesilute in multi-tissue aging studies, enabling researchers to draw comparisons between vascular and myocardial aging trajectories under bioregulatory peptide influence.

Arterial Stiffness and Extracellular Matrix Research

• Collagen and elastin gene expression profiling in vascular smooth muscle cells and fibroblasts exposed to Vesilute under normoxic and hypoxic research conditions
• Matrix metalloproteinase (MMP) activity assays examining extracellular matrix remodeling enzymes in vascular tissue preparations
• Atomic force microscopy studies measuring biomechanical properties of cell monolayers and extracellular matrix gels in the presence of bioregulatory peptide signals
• Crosslinking enzyme (lysyl oxidase) expression analysis relevant to collagen maturation and arterial wall compliance in aging models

Laboratory Handling and Storage Protocols

Lyophilized Storage

• Store lyophilized Vesilute at −20°C in a frost-free freezer, protected from light and moisture
• Desiccant pouches should be included in storage containers to minimize ambient humidity exposure during long-term archiving
• Avoid repeated freeze-thaw cycling of lyophilized material; aliquot powder into single-use research quantities prior to first use
• Lyophilized product is stable for up to 24 months under recommended conditions when packaging integrity is maintained

Reconstitution Guidelines

• Reconstitute in sterile bacteriostatic water or phosphate-buffered saline (PBS, pH 7.4) at the lowest volume consistent with required experimental concentrations
• Allow vial to equilibrate to room temperature before opening to prevent condensation-related contamination of the lyophilized powder
• Add solvent gently along the vial wall and swirl slowly; avoid vigorous vortexing which may cause peptide aggregation or shearing
• Confirm complete dissolution visually prior to aliquoting for experimental use; filter through a 0.22 µm membrane if sterility is required for cell-based assays

Reconstituted Solution Storage

• Store reconstituted Vesilute solutions at 4°C for short-term use (up to 7 days) or at −80°C for extended storage periods
• Prepare single-use aliquots prior to freezing to eliminate repeated freeze-thaw degradation cycles
• Label all aliquots with concentration, date of reconstitution, and lot number to support research traceability requirements

Quality Assurance and Analytical Testing

• Purity Analysis (HPLC): Each batch of Vesilute is characterized by reverse-phase high-performance liquid chromatography (RP-HPLC) with UV detection at 220 nm. Purity ≥98% is confirmed prior to release, ensuring suitability for reproducible laboratory investigations.
• Structural Verification (ESI-MS): Electrospray ionization mass spectrometry (ESI-MS) confirms the molecular weight and sequence integrity of each production lot, providing identity confirmation for the KED tripeptide structure.
• Contaminant Testing: Testing for residual solvents, heavy metals, and endotoxin (LAL assay, <1 EU/mg) is performed on each batch. Endotoxin control is particularly important for cell-based assays where lipopolysaccharide contamination could confound vascular inflammatory endpoint measurements.
• Documentation: A certificate of analysis (CoA) is provided with each research order, documenting purity, mass spectrometric data, and lot-specific test results. CoA documentation supports research reproducibility and regulatory compliance within institutional laboratory frameworks.

Research Considerations

Researchers designing Vesilute-based experiments should account for the following experimental design factors:

1. Establish appropriate vehicle controls matched to the reconstitution solvent used for Vesilute to isolate peptide-specific effects from solvent-induced responses in vascular cell cultures
2. Characterize cell passage number and senescence status of endothelial cell lines prior to use, as replicative age significantly influences baseline gene expression profiles
3. Include positive control peptides or known endothelial regulators in experimental panels to validate assay sensitivity and contextual biological responsiveness
4. Account for potential serum protein interactions when using Vesilute in serum-containing culture media; consider parallel serum-free experiments to clarify binding effects
5. Pre-validate batch-to-batch consistency using a standardized cellular bioassay when transitioning between research lots to ensure experimental continuity

Mechanistic investigations into Vesilute’s vascular biology interactions may examine:

• Interaction with nuclear transcription factors including NF-κB, AP-1, and Nrf2 pathways implicated in endothelial inflammatory and oxidative stress responses
• Chromatin immunoprecipitation (ChIP) assays to identify genomic loci exhibiting altered histone modification patterns in Vesilute-treated vascular cell populations
• Single-cell RNA sequencing to characterize transcriptional heterogeneity in endothelial responses to bioregulatory peptide exposure across arterial versus venous cell subtypes
• Protein-protein interaction assays to map the molecular partners through which the KED sequence exerts its proposed transcriptional modulatory effects

Compliance and Safety Information

• Regulatory Status: Vesilute is supplied exclusively as a research compound for laboratory use. It has not been evaluated or approved by the FDA, EMA, or any other regulatory authority for human or veterinary medical use.
• Intended Use: This material is intended solely for in vitro laboratory research and preclinical investigations by qualified scientific personnel operating within institutionally approved research programs.
• NOT Intended For: Human consumption, in vivo administration to humans, veterinary use, food, drug, cosmetic, or household applications. Not for use by individuals outside of professional research settings.
• Safety Protocols: Handle according to institutional biosafety guidelines. Use appropriate personal protective equipment (gloves, lab coat, eye protection) when handling lyophilized powders or reconstituted solutions. Consult the material safety data sheet (MSDS) provided with shipment. Dispose of research materials in compliance with applicable institutional and governmental regulations.